In January 2024, Noland Arbaugh, a 29-year-old left paralysed from the shoulders down by a diving accident, became the first person to receive a Neuralink brain implant. The device, called the N1, is a coin-sized chip placed in the part of the brain that plans movement, with 64 fine threads carrying 1,024 electrodes into the tissue, all put in place by a surgical robot. Within weeks Arbaugh was moving a computer cursor, playing chess and playing video games using thought alone. A second patient, known as Alex, followed a few months later and was using the implant for computer-aided design work, and a third, Brad Smith, who has motor neurone disease and cannot speak, received his in late 2024 and began communicating through decoded brain signals. By early 2026, twenty-one people in four countries had received the implant, including the first patient in Britain in October 2025, and the trial continues to grow.
What the Evidence Shows
The technology is still experimental, and the first patient showed why caution is needed: some of the implant’s threads pulled out of place in the months after surgery, cutting the number of working electrodes, though a software update restored much of the performance and later patients had the problem designed out. The surgery itself carries real risks, and the device is only offered to people with severe paralysis or motor neurone disease for whom the benefit outweighs the danger. Other companies are taking different routes: Synchron places its device through a blood vessel, avoiding open brain surgery altogether, and academic teams have already restored speech and movement with research implants. The price, who pays for it and who controls the data are questions for later, but the direction is clear. For people who cannot move or speak, a chip that turns thought into action is no longer science fiction. Reporting and analysis from sources such as Wired track the same developments, and specialists following brain-computer interfaces say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is an industry learning to ship capability and restraint together. Products built around brain-computer interfaces now launch with safety evaluations, usage data and rollback plans as standard, because enterprise buyers and regulators ask for them in the first meeting. Companies that treated those questions as friction are discovering they have become the purchase criteria.
What Happens Next
What happens next for brain-computer interfaces depends less on another breakthrough than on the unglamorous work of reliability, pricing and support. The buyers evaluating it now are not enthusiasts; they are operators with budgets and auditors, and their checklists will decide the timeline. On the evidence of the current pilots, the technology has earned the right to be judged by them. You can follow related developments in our coverage of technology.
None of this will be settled by a single announcement, study or product launch. The pattern to watch is accumulation: independent confirmations, honest reporting of failures and steady improvement in the underlying numbers. Readers who follow those signals, rather than the loudest claim of the week, will understand this subject better than most of the commentary surrounding it suggests is possible.
